FDA posts draft Q&A clarifying three-year drug exclusivity rules

The Federal Register posted a Food and Drug Administration draft guidance titled "New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers" on March 4, 2026, signaling a formal move to clarify when manufacturers may qualify for three-year exclusivity tied to new clinical investigations. The guidance, listed on the FDA website as content current as of March 2, 2026 and filed in the Federal Register on March 3, 2026 at 8:45 a.m., is intended to help applicants preparing requests for new clinical investigation exclusivity for new drug applications and NDA supplements.

The document is labeled "Not for implementation. Contains non-binding recommendations." It lays out statutory and regulatory criteria for eligibility, recommends the content and format of exclusivity requests, and is organized as a question and answer resource. FDA says it intends to update the draft with additional Q&As as appropriate. The filing carries docket number FDA-2024-D-4388.

The notice opens a 60-day public comment period measured from the date of Federal Register publication. The agency’s standard language appears in the posting: submit electronic or written comments by the deadline to ensure FDA considers them before work on a final guidance begins. Commenters should identify submissions with docket FDA-2024-D-4388 and may file electronically via the Federal eRulemaking Portal or by mail to Dockets Management, Food and Drug Administration, 5630 Fishers Lane, Rm 1061, Rockville, MD 20852. The Federal Register notice reiterates that electronic comments, including attachments, will be posted to the docket unchanged and cautions that submitters are solely responsible for avoiding confidential information in public filings.

The draft guidance also includes a Paperwork Reduction Act notice and seeks comment on proposed collections of information; the Federal Register entry repeats the standard 60-day PRA comment notice required before submission to the Office of Management and Budget. Because the public inspection version on FederalRegister.gov is an XML rendition, the posting carries a technical caveat advising users to verify the Federal Register text against the official PDF available on govinfo.gov.

Industry stakeholders are likely to read the guidance as a roadmap for both seeking exclusivity and contesting claims. The guidance arrives amid high-profile disputes over three-year exclusivity that have affected market entry. Agency records and filings show that FDA previously awarded three additional years of exclusivity to a follow-on inhaled treprostinil product, Tyvaso DPI, a decision that delayed a competitor’s launch of Yutrepia until May 2025; that contested award rested in part on a clinical program known as the BREEZE trial, which enrolled 51 patients. Critics have argued that inconsistent agency determinations can extend monopoly periods and tilt incentives away from innovation.

For companies, attorneys and patient groups, the draft Q&A is a consequential procedural document: it clarifies the evidentiary and formatting expectations for exclusivity petitions and may narrow the scope for later legal challenges. Stakeholders should download the official Federal Register PDF and the FDA guidance PDF to confirm the final comment deadline and submission URLs, and they should consider filing comments within the 60-day window to shape the agency’s final guidance.